CX co-chairs Dittmar Bӧckler (University Hospital Heidelberg, Heidelberg, Germany) and Andrew Holden (Auckland City Hospital, Auckland, New Zealand) discuss with Marc Schermerhorn (Beth Israel Deaconess Medical Center, Boston, USA) the unmet need in EVAR and the failure of some sacs to regress after implantation and a possible solution being evaluated in the AAA-SHAPE Pivotal Trial.
Holden highlighted data from the AAA-SHAPE early feasibility studies that evaluated the IMPEDE-FX embolisation plug for the management of AAA sacs at the time of EVAR. This novel technology is comprised of shape memory polymer, a porous polyurethane scaffold that supports rapid conversion to organised thrombus, which Holden reports could lead to sac shrinkage.
Schermerhorn also highlighted the need for evidence from a randomised clinical trial and announced the initiation of the AAA-SHAPE Pivotal Trial.
This video is sponsored by Shape Memory Medical.
LIT1183 Rev A
